sch 717454 in subjects with relapsed osteosarcoma or ewing’s sarcoma protocol p04720 ctos nov 2008
TRANSCRIPT
SCH 717454 in Subjects with Relapsed
Osteosarcoma or Ewing’s Sarcoma
Protocol P04720
CTOS Nov 2008
2
Disclosure
• Neither I , nor my colleagues have any stock nor have we been paid consultants of Schering-Plough
• Investigators have received research funds for this study (P04720).
3
Insulin Growth Factor Pathway
IGF-II/IGF-I
IGF-1R
PP
PERK1/2
AKT
4
SCH 717454: A Potent & Specific anti-IGF-1R Monoclonal Antibody
High Affinity Fully Human IgG1 clone 19D12
Does Not Recognize Insulin Receptor
Properties and Activities That May Contribute To Antitumor Effects:
• Inhibits IGF ligand binding and IGF-1R signaling
• Downregulation of IGF-1R protein level
• Antibody-dependent cellular cytotoxicity
• Enhances other agents in pre-clinical studies
IGF-1R IGF-1R/IR
dimer
InsulinReceptor
(IR)
5
SCH717454 & Osteosarcoma Xenografts
• Inhibits osteosarcoma, Ewing’s sarcoma & neuroblastoma xenografts
• Pediatric preclinical testing program: complete responses in 2 out of 6 osteosarcoma (OS1, OS9) & 1 Ewing’s sarcoma cell line (EW5). Improved Event Free survival in 4/6 osteosarcoma and 2/5 Ewing’s models.
•Kolb, Gorlick et al. 2008
SCH 717454 Inhibits SJSA-1 Growth in vivo
Staged model, 2 x weekly
SCH 717454 Causes Regression of OS-1 in vivo (PPTP / NCI)
1 2 3 4 5 60
4.0
3.0
2.0
1.0
0.0
Treatment
Control
Rel
ativ
e T
um
or
Vo
lum
e
Time (weeks)
0
250
500
750
1000
1250
1500
1750
2000
0 2 4 6 8 10 12 14 16 18 20 22 24
Days (post dosing)
Tu
mo
r S
ize
(m
m3 )
Vehicle Control 0.02 mg SCH 7174540.1 mg SCH 7174540.5 mg SCH 717454
Staged model, starting tumor volume: 250 mm3, 0.5 mg SCH 717454, 2 x weekly
6
Endpoints Primary: Response Secondary: TTP, Safety, PK, PD
Recurrent/refractoryOsteosarcoma or Ewing’s Sarcoma(N25-50 each)
Recurrent/refractoryOsteosarcoma or Ewing’s Sarcoma(N25-50 each)
SCH 717454 10 mg/kg
Q 2 weeks
SCH 717454 10 mg/kg
Q 2 weeks
Refractory Osteosarcoma or Ewing’s Sarcoma Cohorts
7
Key Inclusion/Exclusion Criteria
• Key Inclusions– ≥11 years of age – Osteosarcoma or Ewing’s sarcoma
• Key Exclusions
– Diabetics: hemoglobin A1C >7.5% – Heart disease, hepatitis or active infection– Prior anti-IGF-1R drug
8
Serum IGF-1 Concentrations During Treatment
0
100
200
300
400
500
600
700
Baseline 2 wks after Single Dose (Trough Level)
SubsequentDoses (at Trough)
IGF
-1 b
loo
d le
ve
l (n
g/m
l)
9
IGF-1R Occupancy On Peripheral Blood Mononuclear Cells
0
10
20
30
40
50
60
Baseline Two Weeks Post-Dose (Obtained at Trough)
% o
f IG
F-1
R u
n-o
ccu
pie
d Flow cytometry assay measuring the percent of cells that bind labeled SCH
717454at baseline (blue)
versus2 weeks post single dose of
SCH 717454 (purple)
10
Preliminary Response Data
• Osteosarcoma: stable disease in >5* (1 stable to >6 months; another ongoing response with both lung and bone metastases)
• Ewings: 3 PRs; some of subjects with mixed responses
*Initial data on subject at 8 weeks on study
11
Preliminary Ewing’s Response
Before After Single Dose
11 year old female with recurrent/refractory Ewing’s Sarcoma s/p 3 prior therapies
12
Responding Ewing’s Sarcoma
Before After (8 weeks)
29 year old male with recurrent/refractory Ewing’s Sarcoma s/p 3 prior therapies
13
Near Complete Response in Ewing’s
Before at 8 week assessment
28 year old male with recurrent/refractory Ewing’s Sarcoma s/p 2 prior therapies
14
Most Common Adverse Events
Adverse EventIncidence
Grade 1 Grade 2 Grade 3 Grade 4
Headache 5 (8%) 1 (2%) 0 0
Fatigue 1 (2%) 3 (5%) 0 0
Hyperglycemia 3 (5%) 0 1 (2%) 0
Pruritus 3 (5%) 1 (2%) 0 0
Nausea 3 (5%) 1 (2%) 0 0
Back Pain 0 0 3 (5%) 0
Constipation 1 (2%) 1 (2%) 1 (2%) 0
Dyspnoea 1 (2%) 1 (2%) 1 (2%) 0
Pneumothorax 2 (3%) 0 1 (2%) 0
15
Safety/Tolerability Summary
• Well tolerated
– Most AEs mild or moderate
• Hyperglycemia
– Generally mild if present
– Only 1 moderate/severe event in an adult diabetic
– No severe or life-threatening drug-related AEs
16
P04720: Group 1
Recurrence
TTP
ResectableDisease
ResectableDisease
SCH 717454 Dose Level
1
SCH 717454 Dose Level
1
Prior Surgery
Prior Surgery
Recurrence
Surgery
SCH 717454 Dose Level 2SCH 717454 Dose Level 2
Tumor Proliferation
Tumor Proliferation
TTP
SCH 717454 Dose Level
1
SCH 717454 Dose Level
1
SCH 717454 Dose Level
2
SCH 717454 Dose Level
2
Primary Endpoint: tumor proliferation Secondary Endpoint: TTP/Time to relapse
17
Summary
• Potent in preclinical models
• Clinically well-tolerated
– Hyperglycemia uncommon, mostly mild
• Clinically active in Ewing’s sarcoma
• Stable disease in Osteosarcoma
• Enrollment continuing- North America, Europe, and South America
18
Acknowledgements
• Contributing Investigators
– Drs. Anderson, Skubitz, Miller, Meyer, Arico, Mita, Chawla, Katzenstein, O’Day, Desai, Villarroel, Lopez, Van de Graaf, Mas, Sandoval, Marec-Berard, Jean-Gentet, Bielack, and Klingelbiel
• Schering Plough Personnel– Drs. Lu, and Wang; Ms. Whitman
• All the patients and their families
• ? Questions?